200+ Lawsuits Claim GLP-1 Drugs Caused Blindness

Over 200 lawsuits are currently filed in federal court, accusing manufacturers of GLP-1 drugs of causing nonarteritic anterior ischemic optic neuropathy (NAION). This condition results in sudden, irreversible vision loss. Plaintiffs contend that companies like Novo Nordisk and Eli Lilly knew about the potential risk and did not sufficiently warn consumers.

One plaintiff, Edward Gillen, described losing his sight within days, which doctors linked to his Ozempic prescription. He now faces the challenge of relearning daily life activities. Experts explain NAION as a blockage of blood flow to the optic nerve, akin to a stroke, with no available treatment.

While recent studies from 2024 suggest a possible link between semaglutide (found in Ozempic) and NAION, they also emphasize the low overall risk. Organizations like the North American Neuro-Ophthalmology Society state the risk magnitude is low. However, a key challenge is that many patients using GLP-1s already have risk factors for NAION, such as diabetes and hypertension.

Novo Nordisk stated that they believe the lawsuits are without merit and are defending their products in court, emphasizing the well-established safety profile of semaglutide with extensive patient exposure. Meanwhile, Gillen's community has initiated fundraising efforts to support individuals affected by vision loss.